Cardiac Failure Review (May 2021)

Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab

  • Ava Diarra,
  • Guillaume Gantois,
  • Mouna Lazrek,
  • Basile Verdier,
  • Vincent Elsermans,
  • Hélène Zephir,
  • Benjamin Longère,
  • Xristos Gkizas,
  • Céline Goeminne,
  • Gilles Lemesle,
  • Francis Juthier,
  • Johana Bene,
  • David Launay,
  • Romain Dubois,
  • Sandrine Morell-Dubois,
  • Fanny Vuotto,
  • Anne-Laure Piton

DOI
https://doi.org/10.15420/cfr.2020.33
Journal volume & issue
Vol. 7

Abstract

Read online

Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses – in particular, the Coxsackie B viruses – are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.